eligibility_summary
Eligible: AML, age 60–80 newly diagnosed, untreated (hydroxyurea/pre‑chemo allowed) or 14–60 not HSCT‑eligible, KPS ≥60%/ECOG ≤2, life expectancy ≥3 mo, labs adequate (ALT/AST/bilirubin ≤3×ULN, Cr ≤2×ULN or CrCl ≥40), LVEF >50%, donor 0–3/10 HLA match, same blood type, consent. Exclude: other malignancy, post‑chemo marrow failure, major surgery <4wk, severe cardiac disease, HIV/HBV/HCV, stroke/ICH <6 mo, need warfarin/VKA, mental/cognitive illness, recent/ongoing trials, investigator discretion
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm AML study testing: 1) Unrelated umbilical cord blood microtransplantation (cell therapy): infusion of HLA 0–3/10–mismatched donor hematopoietic stem/immune cells during chemotherapy without immunosuppression to induce transient microchimerism and graft‑versus‑leukemia (GVL) via donor T/NK alloreactivity, with limited GVHD and hematopoietic support. 2) Venetoclax (small‑molecule BH3 mimetic): selective BCL‑2 inhibitor that triggers mitochondrial apoptosis in AML cells. 3) Decitabine or azacitidine (nucleoside hypomethylating agents): inhibit DNA methyltransferase, causing DNA hypomethylation, gene re‑expression, differentiation/apoptosis, and sensitization to venetoclax. Targets/pathways: AML blasts, intrinsic apoptosis pathway (BCL‑2/MOMP), epigenetic regulation (DNMT), and allo‑immune cytotoxicity (donor T/NK‑cell GVL).